Related Experiment Video
Updated: Feb 13, 2026

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan
Published on: August 27, 2019
Neonatal and Pediatric Candidemia: Results From Population-Based Active Laboratory Surveillance in Four US Locations,
Kaitlin Benedict1, Monika Roy1, Sarah Kabbani2
1Mycotic Diseases Branch, Division of Foodborne, Waterborne, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Insights
Pediatric candidemia, a bloodstream infection, saw declining incidence in infants and children after 2009. However, rates stabilized from 2012-2015, with uncommon antifungal resistance. Further research is needed to understand these trends.
Area of Science:
- Infectious Diseases
- Epidemiology
- Pediatric Health
Background:
- Candida species are a major cause of healthcare-associated bloodstream infections (candidemia) in the US.
- Pediatric populations exhibit unique risk factors and Candida species distribution compared to adults.
- Recent epidemiological data on pediatric candidemia is limited.
Purpose of the Study:
- To describe the epidemiology of candidemia in children in the United States.
- To analyze trends in incidence, clinical features, species distribution, and antifungal drug resistance.
- To provide updated insights into a critical pediatric infection.
Main Methods:
- Active, population-based candidemia surveillance was conducted in four US metropolitan areas from 2009 to 2015.
- Incidences were calculated for neonates (0-30 days), infants (0-364 days), and noninfant children (1-19 years).
- Clinical features and antifungal drug resistance patterns were documented.
Main Results:
- A total of 307 pediatric candidemia cases were identified.
- Incidence decreased in neonates and infants after 2009, stabilizing between 2012-2015. Noninfant children showed a steady decrease.
- Common conditions included prematurity (neonates), surgery (infants), and malignancy (children). *Candida albicans* dominated neonate cases, while non-*C. albicans* species were more frequent in older children. Antifungal resistance was low, with a 30-day crude mortality of 13%.
Conclusions:
- Candidemia incidence in neonates and infants declined post-2009 but stabilized in recent years (2012-2015).
- Antifungal drug resistance remains uncommon in pediatric candidemia.
- Further investigation is warranted to understand the reasons behind the lack of continued decline in neonatal and infant candidemia incidence.
Introduction:
Candida is a leading cause of healthcare-associated bloodstream infections in the United States. Infants and children have unique risk factors for candidemia, and the Candida species distribution in this group is different that among adults; however, candidemia epidemiology in this population has not been described recently.
Methods:
We conducted active population-based candidemia surveillance in 4 US metropolitan areas between 2009 and 2015. We calculated incidences among neonates (0-30 days old), infants (0-364 days old), and noninfant children (1-19 years old), documented their clinical features and antifungal drug resistance.
Results:
We identified 307 pediatric candidemia cases. Incidence trends varied according to site, but overall, the incidence in neonates decreased from 31.5 cases/100000 births in 2009 to 10.7 to 11.8 cases/100000 births between 2012 and 2015, the incidence in infants decreased from 52.1 cases/100000 in 2009 to 15.7 to 17.5 between 2012 and 2015, and the incidence in noninfant children decreased steadily from 1.8 cases/100000 in 2009 to 0.8 in 2014. Common underlying conditions were prematurity in neonates (78%), surgery in nonneonate infants (38%), and malignancy in noninfant children (28%). Most neonate cases were caused by C albicans (67%), whereas non-C. albicans species accounted for 60% of cases in nonneonate infants and noninfant children. Fluconazole and echinocandin resistance rates were low overall. Thirty-day crude mortality was 13%.
Conclusions:
The incidence of candidemia among neonates and infants declined after 2009 but remained stable from 2012 to 2015. Antifungal drug resistance is uncommon. Reasons for the lack of recent declines in neonatal and infant candidemia deserve further exploration. In this article, we describe the epidemiology of candidemia in children in the United States and on the basis of data collected as part of US Centers for Disease Control and Prevention active population-based surveillance. Trends in incidence, clinical characteristics, species distribution, and resistance rates are presented.
Related Concept Videos
Principles of Disease Surveillance
Conservation of Small Populations
What is Population Genetics?
Population Growth
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
What are Populations and Communities?

